HomeENGLISH MAGAZINEPre-IBD broods in silence: and those "bloody" markers hatch years earlier

Pre-IBD broods in silence: and those “bloody” markers hatch years earlier

Ulcerative colitis is an inflammatory bowel disease (IBD), with symptoms normally setting in between late adolescence and the age of 30. What causes it is not yet known, but there are lots to suggest that the disease is a result of an interplay between genetic and environmental factors and that gut flora definitely plays a part. After the first symptoms, the diagnosis of the bowel disease ulcerative colitis may take a few months. As shown in a study at örebro University, there is, however, a precursor to the disease already several years before its onset. One problem for research is that once the disease has flared up, the immune system is under such stress that any factors that do have an impact, risk drowning in the noise of the severe inflammation. Instead of looking for clues in the hyperactive immune system of those affected by the disease, in this study, researchers chose to go back in time to find out what happens before the onset of the symptoms of ulcerative colitis. This opportunity is offered via the “Northern Sweden Health and Disease Study”, where blood samples from a large group of individuals have been collected on a regular basis since the 1980s.

Daniel Bergemalm, physician and researcher on gastrointestinal diseases at Örebro University, explained: “This is the first time that research has been able to identify, in detail, the type of inflammation that exists in healthy individuals who later in life develop ulcerative colitis. The blood samples provided us with a unique opportunity to do a first major study of the causes of ulcerative colitis. We could access blood samples from individuals who were healthy at the time of sampling, but who developed the disease later in life. The time between the blood samples and the onset of the disease varied between 1 and 15 years. We were able to see patterns in some 90 selected inflammation molecules and of these proteins identify six specific ones. It turns out that four of the six proteins we’d identified were also found in the healthy twins, which indicates that a combination of genetic and environmental factors contributes to these four proteins being activated. We already knew that the level of some of these proteins increased in individuals with ulcerative colitis”.

The research team proceeded to test the six proteins against a European collaboration that lists patients with established ulcerative colitis, and had their findings confirmed. In addition, the researchers in the study have compared blood samples from sets of twins where one has ulcerative colitis and the other does not. The twins both share genetic profiles and have grown up in the same environment. Finding these six proteins brings the researchers one step closer to understanding the causes of ulcerative colitis. The researchers don’t know if this kind of protein change can also be found in other inflammatory diseases. But it can become a part of the treatment once they know what triggers the disease. The research is now to be extended to include further biobanks. The number of proteins examined is also to be extended – from some 90 original ones in the study to several hundred – to enable researchers to paint a better picture of how the immune system as a whole is linked to bowel disease. Proteomics proved which proteins were moslty involved; among these interleukins (IL-1, IL-8, IL-18, OSM) and adhesion molecules (EPCAM, ITGAV, SLAMF7).

Dr. Bergemalm added and concluded: “For the first time, we were able to see that they were also present in healthy individuals long before they developed any symptoms. Today, there are no definite ways of preventing ulcerative colitis. Unfortunately, as physicians, we have no lifestyle advice to offer. There really aren’t enough studies for us to draw any conclusions and give advice on diet, even if the gut flora probably does play a part. I believe dietary advice and probiotics as having the potential for preventing the disease in the future. The liquid diet some children with ulcerative colitis are on is very effective. But there are few adults in the world who would tolerate getting their nutrition via a tube. Ulcerative colitis is treated with different drugs: it is possible that we in the future could use blood samples from individual patients, to see what has caused the disease in that particular person – and on that basis tailor the drug treatment”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Eriksson C et al. Scand J Gastroenterol. 2021 Aug 20:1-8.

Bergemalm D et al. Gastroenterology 2021 Jul 20.

Kalla R et al. J Crohns Colitis. 2021 May 4; 15(5):699-708.

The following two tabs change content below.

Dott. Gianfrancesco Cormaci

Medico Chirurgo, Specialista; PhD. a CoFood s.r.l.
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento enzimaticamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (Leader of the R&D for the partnership CoFood s.r.l.) - Autore di articoli su informazione medica e salute sul sito www.medicomunicare.it (Medical/health information on website) - Autore di corsi ECM FAD pubblicizzati sul sito www.salutesicilia.it
- Advertisment -